 |
市場調查報告書
商品編碼
1136933
緩解疾病性抗風濕藥市場:各藥物類型，適應症，流通管道，地區-規模，佔有率，展望，機會分析，2022-2030年Disease-Modifying Antirheumatic Drug Market, by Drug Type (Synthetic, (Conventional synthetic, Targeted synthetic DMARDs, Biological DMARDs, Indication, Distribution Channel, & Region-Size, Share, Outlook, & Opportunity Analysis, 2022-2030 |
||||||
價格
簡介目錄
市場動態
在全球改善疾病的抗風濕藥 (DMARDs) 市場上運營的主要參與者正專注於增加產品發布和產品批准，預計這將在預測期內推動市場增長。
本調查的主要特徵
- 本報告提供以2021年為基準年的預測期間（2022-2030 年）之全球緩解疾病性抗風濕藥市場的市場規模和復合年增長率（CAGR %）相關的詳細分析。
- 並闡明不同部門市場的潛在收入機會，說明該市場具有魅力的投資主張矩陣。
- 同時並提供市場推動因素和限制、機會、新產品發布或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
- 並基於企業亮點，各類型投資組合、主要焦點、財務業績和市場策略等參數，介紹全球緩解疾病性抗風濕藥市場的主要參與者之企業簡介。
- 藉由該報告提供的洞察，將能幫助營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
- 全球緩解疾病性抗風濕藥市場報告配合該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
- 利益相關者可以透過全球緩解疾病性抗風濕藥市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。
目錄
第1章 調查目的與前提條件
- 調查目的
- 前提條件
- 簡稱的說明
第2章 市場展望
- 報告內容
- 市場定義和範圍
- 摘要整理
- 市場概述:各藥物類型
- 市場概述:各藥物給藥途徑
- 市場概述:各適應症
- 各流通管道的市場概述
- 市場概述:各地區
- 連貫·機遇·地圖(COM)
第3章 市場動態，法規，及趨勢的分析
- 市場動態
- 促進因素
- 阻礙因素
- 商機
- 影響分析
- 法規方案
- 市場趨勢
- 主要的發展情形
- 流行病學
- PEST分析
- 聯盟與收購
- 波特分析
- 開發平台分析
第4章 緩解疾病性抗風濕藥(DMARD)的全球市場:冠狀病毒(COVID-19)疫情的影響
- 經濟的影響
- 需求與供給的影響
- COVID-19 影響評估
第5章 緩解疾病性抗風濕藥(DMARD)的全球市場:各藥物類型，2017年～2030年
- 合成藥(sDMARD)
- 傳統合成DMARDs(csDMARDs)
- 標的型合成DMARDs(tsDMARDs)
- 生物製藥(bDMARD)
- 首發品DMARDs(boDMARDs)
- 生物相似藥DMARDs(bsDMARDs)
- 其他
第6章 緩解疾病性抗風濕藥(DMARD)的全球市場:各給藥途徑，2017年～2030年
- 口服劑
- 非口服劑
- 其他
第7章 緩解疾病性抗風濕藥(DMARD)的全球市場:各適應症，2017年～2030年
- 類風濕性關節炎(Rheumatoid Arthritis
- 僵直性脊椎炎
- 乾癬性關節炎
- 全身性紅斑
- 其他
第8章 緩解疾病性抗風濕藥(DMARD)的全球市場:各流通管道，2017年～2030年
- 醫院藥局
- 零售藥局
- 線上藥局
第9章 緩解疾病性抗風濕藥(DMARD)的全球市場:各地區，2017-2030年
- 北美
- 美國
- 加拿大
- 南美
- 巴西
- 墨西哥
- 阿根廷
- 其他的南美地區
- 歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
- 中東地區
- GCC
- 以色列
- 其他的中東地區
- 非洲
- 北非
- 中非
- 南非
第10章 競爭情形
- 熱圖分析
- 市場佔有率分析
- Sanofi.
- Pfizer
- Hoffman-La Roche AG
- Johnson & Johnson
- AbbVie Inc.
- Eli Lilly & Company
- Amgen Inc.
- Swedish Orphan Biovitrum AB
- Bristol-Myers Squibb Company
- UCB S.A.
- Gilead Sciences, Inc.
- Cumberland Pharmaceuticals Inc.
第11章 章節
- 調查手法的介紹
- 關於出版社
簡介目錄
Product Code: CMI5185
Disease-modifying anti-rheumatic drugs (DMARDs) can treat the underlying cause of condition and reduce inflammation. They are given to people with autoimmune conditions, such as rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis and others. These are conditions where the immune system, which normally fights infection, attacks the body's own healthy tissues. DMARDs can improve symptoms such as pain, stiffness and swelling, but they may take a few weeks or even months to fully take effect. There are different types of DMARDs, and they work in slightly different ways. The three main types are: synthetic (sDMARD), targeted synthetic DMARDs, biological DMARDs (bDMARD) and others
Market Dynamics
Key players operating in the global disease-modifying anti-rheumatic drugs (DMARDs) market are focusing on increasing product launches and product approvals which is expected to drive the market growth during the forecast period. For instance, in January 2018, Hetero, one of the leading generic pharmaceutical companies launched its fourth biosimilar drug 'Adalimumab' under the brand name 'Mabura' in India. Mabura is an anti-inflammatory biologic medication specific for human tumor necrosis factor (TNF). It is indicated for the treatment of rheumatoid arthritis and other auto-immune disorders such as psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. Moreover, in September 2020, Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation announced that the U.S. Food and Drug Administration (FDA) approved XELJANZ (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight. This approval makes XELJANZ the first and only Janus kinase (JAK) inhibitor approved in the U.S. for the treatment of pcJIA.
Key features of the study:
- This report provides an in-depth analysis of the global disease-modifying anti-rheumatic drugs (DMARDs) market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global disease-modifying anti-rheumatic drugs (DMARDs) market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
- Key companies covered as a part of this study include Sanofi., Pfizer, F. Hoffman-La Roche AG, Johnson & Johnson, AbbVie Inc., Eli Lilly & Company, Amgen Inc., Swedish Orphan Biovitrum AB, Bristol-Myers Squibb Company, UCB S.A., Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global disease-modifying anti-rheumatic drugs (DMARDs) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global disease-modifying anti-rheumatic drugs (DMARDs) market
Detailed Segmentation:
- Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Market, By Drug Type:
- Synthetic (sDMARD)
- Conventional synthetic (csDMARDs)
- Methotrexate
- Sulfasalazine
- Leflunomide
- Hydroxychloroquine
- Gold Salts
- Targeted synthetic DMARDs (tsDMARDs)
- Biological DMARDs (bDMARD)
- Original DMARDs (boDMARDs)
- Biosimilar DMARDs (bsDMARDs)
- Primary
- Secondary
- Tertiary
- Others
- Synthetic (sDMARD)
- Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Market, By Route of Administration :
- Oral
- Parenteral
- Others
- Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Market, By Indication :
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Systemic Lupus Erythematosus
- Others
- Rheumatoid Arthritis
- Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Market, By Distribution Channel :
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Market, By Region:
- North America
- By Country
- U.S.
- Canada
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country
- South Africa
- Central Africa
- North Africa
- North America
- Company Profiles
- Sanofi *
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer.
- F. Hoffman-La Roche AG
- Johnson & Johnson
- AbbVie Inc.
- Eli Lilly & Company
- Amgen Inc.
- Swedish Orphan Biovitrum AB
- Bristol-Myers Squibb Company
- UCB S.A.
- Gilead Sciences, Inc.
- Cumberland Pharmaceuticals Inc.
- Sanofi *
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Drug Administration
- Market Snapshot, By Indication
- Market Snapshot, By Distribution Channels
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Regulatory Scenario
- Market Trends
- Key Developments
- Epidemiology
- PEST Analysis
- Collaboration and Acquisition
- Porters Analysis
- Pipeline Analysis
4. Global Disease-Modifying Antirheumatic Drug (DMARD) Market- Impact of Coronavirus (COVID-19) Pandemic
- Economic Impact
- Impact on Demand and Supply
- COVID-19 Impact Assessments
5. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Drug Type, 2017-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Synthetic (sDMARD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
- Conventional synthetic (csDMARDs)
- Methotrexate
- Sulfasalazine
- Leflunomide
- Hydroxychloroquine
- Gold Salts
- Targeted synthetic DMARDs (tsDMARDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
- Biological DMARDs (bDMARD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
- Original DMARDs (boDMARDs)
- Biosimilar DMARDs (bsDMARDs)
- Primary
- Secondary
- Tertiary
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
6. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Route of Drug Administration, 2017-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
7. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Indication, 2017-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Rheumatoid Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Ankylosing Spondylitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Psoriatic Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Systemic Lupus Erythematosus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
8. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Distribution Channel, 2017-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
9. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Region, 2017-2030, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Drug Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Drug Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Drug Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Drug Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Drug Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Drug Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017-2030,(US$ Mn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Sanofi.*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer
- Hoffman-La Roche AG
- Johnson & Johnson
- AbbVie Inc.
- Eli Lilly & Company
- Amgen Inc.
- Swedish Orphan Biovitrum AB
- Bristol-Myers Squibb Company
- UCB S.A.
- Gilead Sciences, Inc.
- Cumberland Pharmaceuticals Inc.
11. Section
- Research Methodology
- About us
